纤溶酶原激活物抑制剂-1 4G/5G多态性与2型糖尿病风险相关。
Plasminogen activator inhibitor-1 4G/5G polymorphism is associated with type 2 diabetes risk.
作者信息
Zhao Luqian, Huang Ping
机构信息
Department of Gerontology Endocrinology, Guangzhou First People's Hospital, Guangzhou Medical University Guangzhou 510180, Guangdong, China.
出版信息
Int J Clin Exp Med. 2013 Sep 1;6(8):632-40. eCollection 2013.
A number of studies were performed to assess the association between plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism and susceptibility to type 2 diabetes (T2DM). However, the results were inconsistent and inconclusive. In the present study, the possible association was investigated by a meta-analysis. Eligible articles were identified for the period up to June 2013. Pooled odds ratios (OR) with 95% confidence intervals (CI) were appropriately derived from random-effects models or fixed-effects models. Fourteen case-control studies with a total of 2487 cases and 3538 controls were eligible. In recessive model, PAI-1 4G/5G polymorphism was associated with T2DM risk (OR = 1.23; 95% CI 1.07-1.41; P = 0.004). In the subgroup analysis by ethnicity, a significant association was found among Asians (OR = 1.27; 95% CI 1.08-1.51; P = 0.005). This meta-analysis suggested that PAI-1 4G/5G polymorphism may be associated with T2DM development.
进行了多项研究以评估纤溶酶原激活物抑制剂-1（PAI-1）4G/5G多态性与2型糖尿病（T2DM）易感性之间的关联。然而，结果并不一致且尚无定论。在本研究中，通过荟萃分析对可能的关联进行了调查。确定了截至2013年6月的符合条件的文章。汇总比值比（OR）及其95%置信区间（CI）通过随机效应模型或固定效应模型适当得出。14项病例对照研究符合条件，共计2487例病例和3538例对照。在隐性模型中，PAI-1 4G/5G多态性与T2DM风险相关（OR = 1.23；95% CI 1.07 - 1.41；P = 0.004）。在按种族进行的亚组分析中，在亚洲人群中发现了显著关联（OR = 1.27；95% CI 1.08 - 1.51；P = 0.005）。该荟萃分析表明，PAI-1 4G/5G多态性可能与T2DM的发生有关。
Zotero 插件